2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 32, Issue 1, 2018, Pages 88-120

  Boer, Christa ^a   Meesters, Michael I ^a   Milojevic, Milan ^a   Benedetto, Umberto ^a   Bolliger, Daniel ^a   von Heymann, Christian ^a   Jeppsson, Anders ^a   Koster, Andreas ^a   Osnabrugge, Ruben L ^a   Ranucci, Marco ^a   Ravn, Hanne Berg ^a   Vonk, Alexander B A ^a   Wahba, Alexander ^a   Pagano, Domenico ^a  

^a NONE

Author keywords

Anticoagulation; Bleeding; Blood transfusion; Cardiac surgery; Coagulation factors; Guidelines; Haemostasis

Indexed keywords

ANTITHROMBOCYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; BLEEDING; BLOOD TRANSFUSION; DUAL ANTIPLATELET THERAPY; HEART SURGERY; HEMOSTASIS; HUMAN; MEDICAL SOCIETY; PATIENT CARE; PEROPERATIVE CARE; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; ADULT; ADVISORY COMMITTEE; CARDIAC ANESTHESIA; EUROPE; PROCEDURES; STANDARDS;

ADULT; ADVISORY COMMITTEES; ANESTHESIA, CARDIAC PROCEDURES; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; EUROPE; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 85030755568     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2017.06.026     Document Type: Review

References (305)

1. Karkouti, K., Wijeysundera, D.N., Yau, T.M., Beattie, W.S., Abdelnaem, E., McCluskey, S.A., et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 44 (2004), 1453–1462.
2. Ranucci, M., Bozzetti, G., Ditta, A., Cotza, M., Carboni, G., Ballotta, A., Surgical reexploration after cardiac operations: why a worse outcome?. Ann Thorac Surg 86 (2008), 1557–1562.
3. Paone, G., Likosky, D.S., Brewer, R., Theurer, P.F., Bell, G.F., Cogan, C.M., et al. Transfusion of 1 and 2 units of red blood cells is associated with increased morbidity and mortality. Ann Thorac Surg 97 (2014), 87–93 discussion 93–4.
4. Frojd, V., Jeppsson, A., Reexploration for bleeding and its association with mortality after cardiac surgery. Ann Thorac Surg 102 (2016), 109–117.
5. Ndrepepa, G., Schuster, T., Hadamitzky, M., Byrne, R.A., Mehilli, J., Neumann, F.J., et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 125 (2012), 1424–1431.
6. Mehran, R., Rao, S.V., Bhatt, D.L., Gibson, C.M., Caixeta, A., Eikelboom, J., et al. Standardized bleeding definitions for cardiovascular clinical trials. A Consensus Report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
7. Alghamdi, A.A., Davis, A., Brister, S., Corey, P., Logan, A., Development and validation of Transfusion Risk Understanding Scoring Tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs. Transfusion 46 (2006), 1120–1129.
8. Ranucci, M., Aronson, S., Dietrich, W., Dyke, C.M., Hofmann, A., Karkouti, K., et al. Patient blood management during cardiac surgery: do we have enough evidence for clinical practice?. J Thorac Cardiovasc Surg, 142, 2011, 249 e1–32.
9. Ferraris, V.A., Brown, J.R., Despotis, G.J., Hammon, J.W., Reece, T.B., Saha, S.P., et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 91 (2011), 944–982.
10. Goudie, R., Sterne, J.A.C., Verheyden, V., Bhabra, M., Ranucci, M., Murphy, G.J., et al. Risk scores to facilitate preoperative prediction of transfusion and large volume blood transfusion associated with adult cardiac surgery. Br J Anaesth 114 (2015), 757–766.
11. Vuylsteke, A., Pagel, C., Gerrard, C., Reddy, B., Nashef, S., Aldam, P., et al. The Papworth Bleeding Risk Score: a stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleeding. Eur J Cardiothorac Surg 39 (2011), 924–930.
12. Karkouti, K., O'Farrell, R., Yau, T.M., Beattie, W.S., Reducing Bleeding in Cardiac Surgery Research Group. Prediction of massive blood transfusion in cardiac surgery. Can J Anesth 53 (2006), 781–794.
13. Al-Khabori, M., Al-Riyami, A.Z., Mukaddirov, M., Al-Sabti, H., Transfusion indication predictive score: a proposed risk stratification score for perioperative red blood cell transfusion in cardiac surgery. Vox Sang 107 (2014), 269–275.
14. Biancari, F., Brascia, D., Onorati, F., Reichart, D., Perrotti, A., Ruggieri, V.G., et al. Prediction of severe bleeding after coronary surgery: the WILL-BLEED Risk Score. Thromb Haemost 117 (2017), 445–456.
15. Ranucci, M., Castelvecchio, S., Frigiola, A., Scolletta, S., Giomarelli, P., Biagioli Predicting transfusions in cardiac surgery: the easier, the better: the Transfusion Risk and Clinical Knowledge score. Vox Sang 96 (2009), 324–332.
16. Kozek-Langenecker, S.A., Ahmed, A.B., Afshari, A., Albaladejo, P., Aldecoa, C., Barauskas, G., et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016. Eur J Anaesthesiol 34 (2017), 332–395.
17. American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. Anesthesiology 122 (2015), 241–275.
18. Sousa-Uva, M., Head, S.J., Thielmann, M., Cardillo, G., Benedetto, U., Czerny, M., et al. Methodology manual for European Association for Cardio Thoracic Surgery (EACTS) clinical guidelines. Eur J Cardiothorac Surg 48 (2015), 809–816.
19. Cantrill, J.A., Sibbald, B., Buetow, S., The Delphi and nominal group techniques in health services research. Int J Pharm Pract 4 (1996), 67–74.
20. Mahla, E., Suarez, T.A., Bliden, K.P., Rehak, P., Metzler, H., Sequeira, A.J., et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 5 (2012), 261–269.
21. Malm, C.J., Hansson, E.C., Akesson, J., Andersson, M., Hesse, C., Shams Hakimi, C., et al. Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: a prospective observational study. Br J Anaesth 117 (2016), 309–315.
22. Mahla, E., Prueller, F., Farzi, S., Pregartner, G., Raggam, R.B., Beran, E., et al. Does platelet reactivity predict bleeding in patients needing urgent coronary artery bypass grafting during dual antiplatelet therapy?. Ann Thorac Surg 102 (2016), 2010–2017.
23. Blome, M., Isgro, F., Kiessling, A.H., Skuras, J., Haubelt, H., Hellstern, P., et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 93 (2005), 1101–1107.
24. Bosch, Y., Al Dieri, R., ten Cate, H., Nelemans, P., Bloemen, S., Hemker, C., et al. Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research article. J Cardiothorac Surg, 8, 2013, 154.
25. Karlsson, M., Ternstrom, L., Hyllner, M., Baghaei, F., Nilsson, S., Jeppsson, A., Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion 48 (2008), 2152–2158.
26. Ranucci, M., Jeppsson, A., Baryshnikova, E., Pre-operative fibrinogen supplementation in cardiac surgery patients: an evaluation of different trigger values. Acta Anaesthesiol Scand 59 (2015), 427–433.
27. Walden, K., Jeppsson, A., Nasic, S., Backlund, E., Karlsson, M., Low preoperative fibrinogen plasma concentration is associated with excessive bleeding after cardiac operations. Ann Thorac Surg 97 (2014), 1199–1206.
28. Gielen, C., Dekkers, O., Stijnen, T., Schoones, J., Brand, A., Klautz, R., et al. The effects of pre- and postoperative fibrinogen levels on blood loss after cardiac surgery: a systematic review and meta-analysis. Interact CardioVasc Thorac Surg 18 (2014), 292–298.
29. Coakley, M., Hall, J.E., Evans, C., Duff, E., Billing, V., Yang, L., et al. Assessment of thrombin generation measured before and after cardiopulmonary by-pass surgery and its association with postoperative bleeding. J Thromb Haemost 9 (2011), 282–292.
30. Reinhöfer, M., Brauer, M., Franke, U., Barz, D., Marx, G., Lösche, W., The value of rotation thromboelastometry to monitor disturbed perioperative haemostasis and bleeding risk in patients with cardiopulmonary bypass. Blood Coagul Fibrinolysis 19 (2008), 212–219.
31. Petricevic, M., Biocina, B., Milicic, D., Konosic, S., Svetina, L., Lekic, A., et al. Bleeding risk assessment using whole blood impedance aggregometry and rotational thromboelastometry in patients following cardiac surgery. J Thromb Thrombolysis 36 (2013), 514–526.
32. Ranucci, M., Baryshnikova, E., Soro, G., Ballotta, A., De Benedetti, D., Conti, D., Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg 91 (2011), 123–129.
33. Ranucci, M., Colella, D., Baryshnikova, E., Di Dedda, U., Hemmings, H.C., Surgical, Clinical Outcome Research Group. Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery. Br J Anaesth 113 (2014), 970–976.
34. Mangano, D.T., Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 347 (2002), 1309–1317.
35. Musleh, G., Dunning, J., Does aspirin 6 h after coronary artery bypass grafting optimise graft patency?. Interact CardioVasc Thorac Surg 2 (2003), 413–415.
36. Smith, P.K., Goodnough, L.T., Levy, J.H., Poston, R.S., Short, M.A., Weerakkody, G.J., et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coron- ary artery bypass grafting cohort: risk-adjusted retrospective data ana- lysis. J Am Coll Cardiol 60 (2012), 388–396.
37. Hansson, E.C., Jideus, L., Aberg, B., Bjursten, H., Dreifaldt, M., Holmgren, A., et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J 37 (2016), 189–197.
38. Gherli, R., Mariscalco, G., Dalen, M., Onorati, F., Perrotti, A., Chocron, S., et al. Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol 1 (2016), 921–928.
39. Douketis, J.D., Spyropoulos, A.C., Kaatz, S., Becker, R.C., Caprini, J.A., Dunn, A.S., et al. Perioperative bridging anticoagulation in patients with atrial fibril- lation. N Engl J Med 373 (2015), 823–833.
40. O'Donnell, M.J., Kearon, C., Johnson, J., Robinson, M., Zondag, M., Turpie, I., et al. Brief communication: preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 146 (2007), 184–187.
41. Medalion, B., Frenkel, G., Patachenko, P., Hauptman, E., Sasson, L., Schachner, A., Preoperative use of enoxaparin is not a risk factor for postoperative bleeding after coronary artery bypass surgery. J Thorac Cardiovasc Surg 126 (2003), 1875–1879.
42. Landenhed, M., Johansson, M., Erlinge, D., Olsson, M.L., Bjursten, H., Fondaparinux or enoxaparin: a comparative study of postoperative bleeding in coronary artery bypass grafting surgery. Scand Cardiovasc J 44 (2010), 100–106.
43. Spyropoulos, A.C., Turpie, A.G., Dunn, A.S., Spandorfer, J., Douketis, J., Jacobson, A., et al. Clinical outcomes with unfractionated heparin or low- molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 4 (2006), 1246–1252.
44. Jones, H.U., Muhlestein, J.B., Jones, K.W., Bair, T.L., Lavasani, F., Sohrevardi, M., et al. Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports. Circulation 106:12 Suppl 1 (2002), I19–I22.
45. Spyropoulos, A.C., Turpie, A.G., Dunn, A.S., Kaatz, S., Douketis, J., Jacobson, A., et al. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). Am J Cardiol 102 (2008), 883–889.
46. Douketis, J.D., Johnson, J.A., Turpie, A.G., Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 164 (2004), 1319–1326.
47. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324 (2002), 71–86.
48. Hastings, S., Myles, P., McIlroy, D., Aspirin and coronary artery surgery: a systematic review and meta-analysis. Br J Anaesth 115 (2015), 376–385.
49. Sun, J.C., Whitlock, R., Cheng, J., Eikelboom, J.W., Thabane, L., Crowther, M.A., et al. The effect of pre-operative aspirin on bleeding, transfusion, myo- cardial infarction, and mortality in coronary artery bypass surgery: a sys- tematic review of randomized and observational studies. Eur Heart J 29 (2008), 1057–1071.
50. Myles, P.S., Smith, J.A., Forbes, A., Silbert, B., Jayarajah, M., Painter, T., et al. Stopping vs. continuing aspirin before coronary artery surgery. N Engl J Med 374 (2016), 728–737.
51. Deja, M.A., Kargul, T., Domaradzki, W., Sta˛cel, T., Mazur, W., Wojakowski, W., Effects of preoperative aspirin in coronary artery bypass grafting: a double-blind, placebo-controlled, randomized trial. J Thorac Cardiovasc Surg 144 (2012), 204–209.
52. Morawski, W., Sanak, M., Cisowski, M., Szczeklik, M., Szczeklik, W., Dropinski, J., et al. Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. J Thorac Cardiovasc Surg 130 (2005), 791–796.
53. Hansson, E.C., Shams Hakimi, C., Astrom-Olsson, K., Hesse, C., Wallen, H., Dellborg, M., et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth 112 (2014), 570–575.
54. Martin, A.C., Berndt, C., Calmette, L., Philip, I., Decouture, B., Gaussem, P., et al. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: an in-vitro study. Eur J Anaesthesiol 33 (2016), 361–367.
55. Yusuf, S., Zhao, F., Mehta, S.R., Chrolavicius, S., Tognoni, G., Fox, K.K., Effects of clopidogrel in addition to aspirin in patients with acute coronary syn- dromes without ST-segment elevation. N Engl J Med 345 (2001), 494–502.
56. Wallentin, L., Becker, R.C., Budaj, A., Cannon, C.P., Emanuelsson, H., Held, C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syn- dromes. N Engl J Med 361 (2009), 1045–1057.
57. Wiviott, S.D., Braunwald, E., McCabe, C.H., Montalescot, G., Ruzyllo, W., Gottlieb, S., et al. Prasugrel versus clopidogrel in patients with acute cor- onary syndromes. N Engl J Med 357 (2007), 2001–2015.
58. Becker, R.C., Bassand, J.P., Budaj, A., Wojdyla, D.M., James, S.K., Cornel, J.H., et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 32 (2011), 2933–2944.
59. Levine, G.N., Bates, E.R., Bittl, J.A., Brindis, R.G., Fihn, S.D., Fleisher, L.A., et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 68 (2016), 1082–1115.
60. Qamar, A., Bhatt, D.L., Current status of data on cangrelor. Pharmacol Ther 159 (2016), 102–109.
61. Fox, K.A., Mehta, S.R., Peters, R., Zhao, F., Lakkis, N., Gersh, B.J., et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coron- ary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 110 (2004), 1202–1208.
62. Held, C., Asenblad, N., Bassand, J.P., Becker, R.C., Cannon, C.P., Claeys, M.J., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 57 (2011), 672–684.
63. Tomsic, A., Schotborgh, M.A., Manshanden, J.S., Li, W.W., de Mol, B.A., Coronary artery bypass grafting-related bleeding complications in pa- tients treated with dual antiplatelet treatment. Eur J Cardiothorac Surg 50 (2016), 849–856.
64. Pickard, A.S., Becker, R.C., Schumock, G.T., Frye, C.B., Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting. Pharmacotherapy 28 (2008), 376–392.
65. Purkayastha, S., Athanasiou, T., Malinovski, V., Tekkis, P., Foale, R., Casula, R., et al. Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis. Heart 92 (2006), 531–532.
66. Kolh, P., Windecker, S., Alfonso, F., Collet, J.P., Cremer, J., Falk, V., et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 46 (2014), 517–592.
67. Ferraris, V.A., Saha, S.P., Oestreich, J.H., Song, H.K., Rosengart, T., Reece, T.B., et al. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann Thorac Surg 94 (2012), 1761–1781.
68. Wallentin, L., P2Y(12) inhibitors: differences in properties and mechan- isms of action and potential consequences for clinical use. Eur Heart J 30 (2009), 1964–1977.
69. Gurbel, P.A., Bliden, K.P., Butler, K., Tantry, U.S., Gesheff, T., Wei, C., et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120 (2009), 2577–2585.
70. Storey, R.F., Bliden, K.P., Ecob, R., Karunakaran, A., Butler, K., Wei, C., et al. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. J Thromb Haemost 9 (2011), 1730–1737.
71. Kwak, Y.L., Kim, J.C., Choi, Y.S., Yoo, K.J., Song, Y., Shim, J.K., Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol 56 (2010), 1994–2002.
72. Savonitto, S., D'Urbano, M., Caracciolo, M., Barlocco, F., Mariani, G., Nichelatti, M., et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ‘bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 104 (2010), 285–291.
73. Patrono, C., Coller, B., FitzGerald, G.A., Hirsh, J., Roth, G., Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004), 234S–264S.
74. Dyke, C.M., Jennings, L.K., Maier, G., Andreou, C., Daly, R., Tamberella, M.R., Preoperative platelet inhibition with eptifibatide during coronary artery bypass grafting with cardiopulmonary bypass. J Cardiovasc Pharmacol Ther 12 (2007), 54–60.
75. De Carlo, M., Maselli, D., Cortese, B., Ciabatti, N., Gistri, R., Levantino, M., et al. Emergency coronary artery bypass grafting in patients with acute myo- cardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors. Int J Cardiol 123 (2008), 229–233.
76. Boeken, U., Litmathe, J., Kurt, M., Feindt, P., Gams, E., CABG-procedures in patients with pretreatment with the GPIIb/IIIa-receptor antagonist tiro- fiban (Aggrastat): modification of perioperative management?. Int J Cardiol 127 (2008), 257–259.
77. Kincaid, E.H., Monroe, M.L., Saliba, D.L., Kon, N.D., Byerly, W.G., Reichert, M.G., Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting. Ann Thorac Surg 76 (2003), 124–128 discussion 8.
78. Ashikhmina, E., Tomasello, N., Connors, J.M., Jahanyar, J., Davidson, M., Mizuguchi, K.A., Type A aortic dissection in a patient on dabigatran: hemostasis post circulatory arrest. Ann Thorac Surg 98 (2014), 2215–2216.
79. Stein, P., Bosshart, M., Brand, B., Schlicker, A., Spahn, D.R., Bettex, D., Dabigatran anticoagulation and Stanford type A aortic dissection: lethal coincidence: case report with literature review. Acta Anaesthesiol Scand 58 (2014), 630–637.
80. Crapelli, G.B., Bianchi, P., Isgro, G., Biondi, A., de Vincentiis, C., Ranucci, M., A case of fatal bleeding following emergency surgery on an ascending aorta intramural hematoma in a patient taking dabigatran. J Cardiothorac Vasc Anesth 30 (2016), 1027–1031.
81. Weltert, L., Rondinelli, B., Bello, R., Falco, M., Bellisario, A., Maselli, D., et al. A single dose of erythropoietin reduces perioperative transfusions in cardiac surgery: results of a prospective single-blind randomized controlled trial. Transfusion 55 (2015), 1644–1654.
82. Weltert, L., D'Alessandro, S., Nardella, S., Girola, F., Bellisario, A., Maselli, D., et al. Preoperative very short-term, high-dose erythropoietin adminis- tration diminishes blood transfusion rate in off-pump coronary artery bypass: a randomized blind controlled study. J Thorac Cardiovasc Surg 139 (2010), 621–626 discussion 6–7.
83. Yoo, Y.C., Shim, J.K., Kim, J.C., Jo, Y.Y., Lee, J.H., Kwak, Y.L., Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology 115 (2011), 929–937.
84. Hogan, M., Klein, A.A., Richards, T., The impact of anaemia and intravenous iron replacement therapy on outcomes in cardiac surgery. Eur J Cardiothorac Surg 47 (2015), 218–226.
85. Matsuda, S., Fukui, T., Shimizu, J., Takao, A., Takanashi, S., Tomoike, H., Associations between preoperative anemia and outcomes after off-pump coronary artery bypass grafting. Ann Thorac Surg 95 (2013), 854–860.
86. Zhang, L., Hiebert, B., Zarychanski, R., Arora, R.C., Cardiovascular Health Research in Manitoba Investigator Group. Preoperative anemia does not increase the risks of early surgical revascularization after myocardial infarction. Ann Thorac Surg 95 (2013), 542–547.
87. Cutrell, J.B., Barros, N., McBroom, M., Luby, J., Minhajuddin, A., Ring, W.S., et al. Risk factors for deep sternal wound infection after cardiac surgery: influence of red blood cell transfusions and chronic infection. Am J Infect Control 44 (2016), 1302–1309.
88. Engoren, M., Schwann, T.A., Habib, R.H., Neill, S.N., Vance, J.L., Likosky, D.S., The independent effects of anemia and transfusion on mortality after coronary artery bypass. Ann Thorac Surg 97 (2014), 514–520.
89. von Heymann, C., Kaufner, L., Sander, M., Spies, C., Schmidt, K., Gombotz, H., et al. Does the severity of preoperative anemia or blood transfusion have a stronger impact on long-term survival after cardiac surgery?. J Thorac Cardiovasc Surg 152 (2016), 1412–1420.
90. Garrido-Martin, P., Nassar-Mansur, M.I., de la Llana-Ducros, R., Virgos-Aller, T.M., Rodriguez Fortunez, P.M., Avalos-Pinto, R., et al. The effect of intraven- ous and oral iron administration on perioperative anaemia and transfusion requirements in patients undergoing elective cardiac surgery: a randomized clinical trial. Interact CardioVasc Thorac Surg 15 (2012), 1013–1018.
91. Johansson, P.I., Rasmussen, A.S., Thomsen, L.L., Intravenous iron isomaltoside 1000 (Monofer(R)) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang 109 (2015), 257–266.
92. Kulier, A., Levin, J., Moser, R., Rumpold-Seitlinger, G., Tudor, I.C., Snyder-Ramos, S.A., et al. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation 116 (2007), 471–479.
93. Karkouti, K., Wijeysundera, D.N., Beattie, W.S., Reducing Bleeding in Cardiac Surgery Investigators. Risk associated with preoperative anemia in cardiac surgery: a multicenter cohort study. Circulation 117 (2008), 478–484.
94. Kozek-Langenecker, S.A., Afshari, A., Albaladejo, P., Santullano, C.A., De Robertis, E., Filipescu, D.C., et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 30 (2013), 270–382.
95. Menkis, A.H., Martin, J., Cheng, D.C., Fitzgerald, D.C., Freedman, J.J., Gao, C., et al. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. Innovations (Phila) 7 (2012), 229–241.
96. Karkouti, K., Wijeysundera, D.N., Yau, T.M., McCluskey, S.A., Chan, C.T., Wong, P.Y., et al. Advance targeted transfusion in anemic cardiac surgical patients for kidney protection: an unblinded randomized pilot clinical trial. Anesthesiology 116 (2012), 613–621.
97. Deppe, A.C., Arbash, W., Kuhn, E.W., Slottosch, I., Scherner, M., Liakopoulos, O.J., et al. Current evidence of coronary artery bypass grafting off-pump versus on-pump: a systematic review with meta-analysis of over 16, 900 patients investigated in randomized controlled trialsdagger. Eur J Cardiothorac Surg 49 (2016), 1031–1041 discussion 41.
98. Puskas, J.D., Martin, J., Cheng, D.C., Benussi, S., Bonatti, J.O., Diegeler, A., et al. ISMICS consensus conference and statements of randomized controlled trials of off-pump versus conventional coronary artery bypass surgery. Innovations (Phila) 10 (2015), 219–229.
99. Anastasiadis, K., Antonitsis, P., Haidich, A.B., Argiriadou, H., Deliopoulos, A., Papakonstantinou, C., Use of minimal extracorporeal circulation improves outcome after heart surgery; a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 164 (2013), 158–169.
100. Harling, L., Warren, O.J., Martin, A., Kemp, P.R., Evans, P.C., Darzi, A., et al. Do miniaturized extracorporeal circuits confer significant clinical benefit without compromising safety? A meta-analysis of randomized controlled trials. ASAIO J 57 (2011), 141–151.
101. Sundermann, S.H., Sromicki, J., Rodriguez Cetina Biefer, H., Seifert, B., Holubec, T., Falk, V., et al. Mitral valve surgery: right lateral minithoracotomy or sternotomy? A systematic review and meta-analysis. J Thorac Cardiovasc Surg 148 (2014), 1989–1995 e4.
102. Falk, V., Cheng, D.C., Martin, J., Diegeler, A., Folliguet, T.A., Nifong, L.W., et al. Minimally invasive versus open mitral valve surgery: a consensus statement of the international society of minimally invasive coronary surgery (ISMICS) 2010. Innovations (Phila) 6 (2011), 66–76.
103. Phan, K., Xie, A., Di Eusanio, M., Yan, T.D., A meta-analysis of minimally invasive versus conventional sternotomy for aortic valve replacement. Ann Thorac Surg 98 (2014), 1499–1511.
104. Tavilla, G., Bruggemans, E.F., Gielen, C.L., Brand, A., van den Hout, W.B., Klautz, R.J., et al. Multicentre randomized clinical trial to investigate the costeffectiveness of an allogeneic single-donor fibrin sealant after coronary artery bypass grafting (FIBER Study). Br J Surg 102 (2015), 1338–1347.
105. Lamy, A., Devereaux, P.J., Prabhakaran, D., Taggart, D.P., Hu, S., Paolasso, E., et al. Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med 366 (2012), 1489–1497.
106. Diegeler, A., Borgermann, J., Kappert, U., Breuer, M., Boning, A., Ursulescu, A., et al. Off-pump versus on-pump coronary-artery bypass grafting in elderly patients. N Engl J Med 368 (2013), 1189–1198.
107. Anastasiadis, K., Murkin, J., Antonitsis, P., Bauer, A., Ranucci, M., Gygax, E., et al. Use of minimal invasive extracorporeal circulation in cardiac surgery: principles, definitions and potential benefits. A position paper from the Minimal invasive Extra-Corporeal Technologies international Society (MiECTiS). Interact CardioVasc Thorac Surg 22 (2016), 647–662.
108. Carless, P.A., Henry, D.A., Anthony, D.M., Fibrin sealant use for minimizing peri-operative allogeneic blood transfusion. Cochrane Database Syst Rev, 2, 2003 CD004171.
109. Abrishami, A., Chung, F., Wong, J., Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis. Can J Anaesth 56 (2009), 202–212.
110. Ker, K., Beecher, D., Roberts, I., Topical application of tranexamic acid for the reduction of bleeding. Cochrane Database Syst Rev, 7, 2013, D010562.
111. Gurian, D.B., Meneghini, A., Abreu, L.C., Murad, N., Matos, L.L., Pires, A.C., et al. A randomized trial of the topical effect of antifibrinolytic epsilon aminocaproic Acid on coronary artery bypass surgery without cardiopulmonary bypass. Clin Appl Thromb Hemost 20 (2014), 615–620.
112. Casalino, S., Stelian, E., Novelli, E., De Jong, A., Renzi, L., Arellano, F., et al. Reduced transfusion requirements with a closed cardiopulmonary bypass system. J Cardiovasc Surg (Torino) 49 (2008), 363–369.
113. Nakahira, A., Sasaki, Y., Hirai, H., Matsuo, M., Morisaki, A., Suehiro, S., et al. Cardiotomy suction, but not open venous reservoirs, activates coagulofibrinolysis in coronary artery surgery. J Thorac Cardiovasc Surg 141 (2011), 1289–1297.
114. Ranucci, M., Balduini, A., Ditta, A., Boncilli, A., Brozzi, S., A systematic review of biocompatible cardiopulmonary bypass circuits and clinical outcome. Ann Thorac Surg 87 (2009), 1311–1319.
115. Landis, R.C., Brown, J.R., Fitzgerald, D., Likosky, D.S., Shore-Lesserson, L., Baker, R.A., et al. Attenuating the systemic inflammatory response to adult cardiopulmonary bypass: a critical review of the evidence base. J Extra Corpor Technol 46 (2014), 197–211.
116. Mahmood, S., Bilal, H., Zaman, M., Tang, A., Is a fully heparin-bonded car-diopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit?. Interact CardioVasc Thorac Surg 14 (2012), 406–414.
117. Carless, P.A., Henry, D.A., Moxey, A.J., O'Connell, D., Brown, T., Fergusson, D.A., Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev, 4, 2010 CD001888.
118. Vermeijden, W.J., Hagenaars, J.A., Scheeren, T.W., de Vries, A.J., Additional postoperative cell salvage of shed mediastinal blood in cardiac surgery does not reduce allogeneic blood transfusions: a cohort study. Perfusion 31 (2016), 384–390.
119. Vonk, A.B., Meesters, M.I., Garnier, R.P., Romijn, J.W., van Barneveld, L.J., Heymans, M.W., et al. Intraoperative cell salvage is associated with reduced postoperative blood loss and transfusion requirements in cardiac surgery: a cohort study. Transfusion 53 (2013), 2782–2789.
120. Zakkar, M., Guida, G., Angelini, G.D., Modified ultrafiltration in adult patients undergoing cardiac surgery. Interact CardioVasc Thorac Surg 20 (2015), 415–421.
121. Boodhwani, M., Williams, K., Babaev, A., Gill, G., Saleem, N., Rubens, F.D., Ultrafiltration reduces blood transfusions following cardiac surgery: a meta-analysis. Eur J Cardiothorac Surg 30 (2006), 892–897.
122. Luciani, G.B., Menon, T., Vecchi, B., Auriemma, S., Mazzucco, A., Modified ultrafiltration reduces morbidity after adult cardiac operations: a prospective, randomized clinical trial. Circulation 104 (2001), I253–I259.
123. Sun, P., Ji, B., Sun, Y., Zhu, X., Liu, J., Long, C., et al. Effects of retrograde autologous priming on blood transfusion and clinical outcomes in adults: a meta-analysis. Perfusion 28 (2013), 238–243.
124. Saczkowski, R., Bernier, P.L., Tchervenkov, C.I., Arellano, R., Retrograde autologous priming and allogeneic blood transfusions: a meta-analysis. Interact CardioVasc Thorac Surg 8 (2009), 373–376.
125. Vandewiele, K., Bove, T., De Somer, F.M., Dujardin, D., Vanackere, M., De Smet, D., et al. The effect of retrograde autologous priming volume on haemodilution and transfusion requirements during cardiac surgery. Interact CardioVasc Thorac Surg 16 (2013), 778–783.
126. Ranucci, M., Baryshnikova, E., Simeone, F., Ranucci, M., Scolletta, S., Moderate-degree acidosis is an independent determinant of postoperative bleeding in cardiac surgery. Minerva Anestesiol 81 (2015), 885–893.
127. Lee, B.R., Song, J.W., Kwak, Y.L., Yoo, K.J., Shim, J.K., The influence of hypothermia on transfusion requirement in patients who received clopidogrel in proximity to off-pump coronary bypass surgery. Yonsei Med J 55 (2014), 224–231.
128. El-Sabbagh, A.M., Toomasian, C.J., Toomasian, J.M., Ulysse, G., Major, T., Bartlett, R.H., Effect of air exposure and suction on blood cell activation and hemolysis in an in vitro cardiotomy suction model. ASAIO J 59 (2013), 474–479.
129. Murphy, G.S., Hessel, E.A. 2nd, Groom, R.C., Optimal perfusion during car-diopulmonary bypass: an evidence-based approach. Anesth Analg 108 (2009), 1394–1417.
130. Lindholm, L., Westerberg, M., Bengtsson, A., Ekroth, R., Jensen, E., Jeppsson, A., A closed perfusion system with heparin coating and centrifugal pump improves cardiopulmonary bypass biocompatibility in elderly patients. Ann Thorac Surg 78 (2004), 2131–2138 discussion 8.
131. Mirow, N., Zittermann, A., Koertke, H., Maleszka, A., Knobl, H., Coskun, T., et al. Heparin-coated extracorporeal circulation in combination with low dose systemic heparinization reduces early postoperative blood loss in cardiac surgery. J Cardiovasc Surg (Torino) 49 (2008), 277–284.
132. Paparella, D., Scrascia, G., Rotunno, C., Marraudino, N., Guida, P., De Palo, M., et al. A biocompatible cardiopulmonary bypass strategy to reduce hemostatic and inflammatory alterations: a randomized controlled trial. J Cardiothorac Vasc Anesth 26 (2012), 557–562.
133. Lorusso, R., De Cicco, G., Totaro, P., Gelsomino, S., Effects of phosphorylcholine coating on extracorporeal circulation management and postoperative outcome: a double-blind randomized study. Interact CardioVasc Thorac Surg 8 (2008), 7–11.
134. Marguerite, S., Levy, F., Quessard, A., Dupeyron, J.P., Gros, C., Steib, A., Impact of a phosphorylcholine-coated cardiac bypass circuit on blood loss and platelet function: a prospective, randomized study. J Extra Corpor Technol 44 (2012), 5–9.
135. Hosoyama, K., Ito, K., Kawamoto, S., Kumagai, K., Akiyama, M., Adachi, O., et al. Poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit can reduce transfusion of platelet products compared to heparincoated circuit during aortic arch surgery. J Artif Organs 19 (2016), 233–240.
136. Thiara, A.S., Mollnes, T.E., Videm, V., Andersen, V.Y., Svennevig, K., Kolset, S.O., et al. Biocompatibility and pathways of initial complement pathway activation with Phisioand PMEA-coated cardiopulmonary bypass circuits during open-heart surgery. Perfusion 26 (2011), 107–114.
137. Carless, P.A., Henry, D.A., Moxey, A.J., O'Connell, D.L., Brown, T., Fergusson, D.A., Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev, 2006, 4 CD001888.
138. Wang, G., Bainbridge, D., Martin, J., Cheng, D., The efficacy of an intraoperative cell saver during cardiac surgery: a meta-analysis of randomized trials. Anesth Analg 109 (2009), 320–330.
139. Weltert, L., Nardella, S., Rondinelli, M.B., Pierelli, L., De Paulis, R., Reduction of allogeneic red blood cell usage during cardiac surgery by an integrated intraand postoperative blood salvage strategy: results of a randomized comparison. Transfusion 53 (2013), 790–797.
140. Engels, G.E., van Klarenbosch, J., Gu, Y.J., van Oeveren, W., de Vries, A.J., Intraoperative cell salvage during cardiac surgery is associated with reduced postoperative lung injury. Interact CardioVasc Thorac Surg 22 (2016), 298–304.
141. Gabel, J., Westerberg, M., Bengtsson, A., Jeppsson, A., Cell salvage of cardiotomy suction blood improves the balance between proand antiinflammatory cytokines after cardiac surgery. Eur J Cardiothorac Surg 44 (2013), 506–511.
142. Damgaard, S., Nielsen, C.H., Andersen, L.W., Bendtzen, K., Tvede, M., Steinbruchel, D.A., Cell saver for on-pump coronary operations reduces systemic inflammatory markers: a randomized trial. Ann Thorac Surg 89 (2010), 1511–1517.
143. Jewell, A.E., Akowuah, E.F., Suvarna, S.K., Braidley, P., Hopkinson, D., Cooper, G., A prospective randomised comparison of cardiotomy suction and cell saver for recycling shed blood during cardiac surgery. Eur J Cardiothorac Surg 23 (2003), 633–636.
144. Rubens, F.D., Boodhwani, M., Mesana, T., Wozny, D., Wells, G., Nathan, H.J., The cardiotomy trial: a randomized, double-blind study to assess the effect of processing of shed blood during cardiopulmonary bypass on transfusion and neurocognitive function. Circulation 116 (2007), I89–I97.
145. Al-Khabori, M., Al-Riyami, A.Z., Baskaran, B., Siddiqi, M., Al-Sabti, H., Discriminatory power of the intraoperative cell salvage use in the prediction of platelet and plasma transfusion in patients undergoing cardiac surgery. Transfus Apher Sci 53 (2015), 208–212.
146. Padhi, S., Kemmis-Betty, S., Rajesh, S., Hill, J., Murphy, M.F., Guideline Development Group. Blood transfusion: summary of NICE guidance. Br Med J, 351, 2015, h5832.
147. Liumbruno, G.M., Waters, J.H., Unwashed shed blood: should we transfuse it?. Blood Transfus 9 (2011), 241–245.
148. Hou, X., Yang, F., Liu, R., Yang, J., Zhao, Y., Wan, C., et al. Retrograde autologous priming of the cardiopulmonary bypass circuit reduces blood transfusion in small adults: a prospective, randomized trial. Eur J Anaesthesiol 26 (2009), 1061–1066.
149. Nathan, H.J., Parlea, L., Dupuis, J.Y., Hendry, P., Williams, K.A., Rubens, F.D., et al. Safety of deliberate intraoperative and postoperative hypothermia for patients undergoing coronary artery surgery: a randomized trial. J Thorac Cardiovasc Surg 127 (2004), 1270–1275.
150. Vonk, A.B., Veerhoek, D., van den Brom, C.E., van Barneveld, L.J., Boer, C., Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery. J Cardiothorac Vasc Anesth 28 (2014), 235–241.
151. Noui, N., Zogheib, E., Walczak, K., Werbrouck, A., Amar, A.B., Dupont, H., et al. Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device. Perfusion 27 (2012), 214–220.
152. Hoenicka, M., Rupp, P., Muller-Eising, K., Deininger, S., Kunert, A., Liebold, A., et al. Anticoagulation management during multivessel coronary artery bypass grafting: a randomized trial comparing individualized heparin management and conventional hemostasis management. J Thromb Haemost 13 (2015), 1196–1206.
153. Wang, J., Ma, H.P., Zheng, H., Blood loss after cardiopulmonary bypass, standard vs titrated protamine: a meta-analysis. Neth J Med 71 (2013), 123–127.
154. Meesters, M.I., Veerhoek, D., de Lange, F., de Vries, J.W., de Jong, J.R., Romijn, J.W., et al. Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery. A randomised clinical trial. Thromb Haemost 116 (2016), 251–261.
155. Avidan, M.S., Levy, J.H., Scholz, J., Delphin, E., Rosseel, P.M., Howie, M.B., et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 102 (2005), 276–284.
156. Avidan, M.S., Levy, J.H., van Aken, H., Feneck, R.O., Latimer, R.D., Ott, E., et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 130 (2005), 107–113.
157. Finley, A., Greenberg, C., Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg 116 (2013), 1210–1222.
158. Hofmann, B., Bushnaq, H., Kraus, F.B., Raspe, C., Simm, A., Silber, R.E., et al. Immediate effects of individualized heparin and protamine management on hemostatic activation and platelet function in adult patients undergoing cardiac surgery with tranexamic acid antifibrinolytic therapy. Perfusion 28 (2013), 412–418.
159. Aziz, K.A., Masood, O., Hoschtitzky, J.A., Ronald, A., Does use of the Hepcon point-of-care coagulation monitor to optimise heparin and protamine dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery?. Interact Cardio Vasc Thorac Surg 5 (2006), 469–482.
160. Pappalardo, F., Franco, A., Crescenzi, G., De Simone, F., Torracca, L., Zangrillo, A., Anticoagulation management in patients undergoing open heart surgery by activated clotting time and whole blood heparin concentration. Perfusion 21 (2006), 285–290.
161. Avidan, M.S., Alcock, E.L., Da Fonseca, J., Ponte, J., Desai, J.B., Despotis, G.J., et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 92 (2004), 178–186.
162. Slight, R.D., Buell, R., Nzewi, O.C., McClelland, D.B., Mankad, P.S., A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 22 (2008), 47–52.
163. Radulovic, V., Laffin, A., Hansson, K.M., Backlund, E., Baghaei, F., Jeppsson, A., Heparin and protamine titration does not improve haemostasis after cardiac surgery: a prospective randomized study. PLoS One, 10, 2015, e0130271.
164. Teoh, K.H., Young, E., Blackall, M.H., Roberts, R.S., Hirsh, J., Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?. J Thorac Cardiovasc Surg 128 (2004), 211–219.
165. Koster, A., Borgermann, J., Gummert, J., Rudloff, M., Zittermann, A., Schirmer, U., Protamine overdose and its impact on coagulation, bleeding, and transfusions after cardiopulmonary bypass: results of a randomized double-blind controlled pilot study. Clin Appl Thromb Hemost 20 (2014), 290–295.
166. Slaughter, T.F., Mark, J.B., El-Moalem, H., Hayward, K.A., Hilton, A.K., Hodgins, L.P., et al. Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation. Blood Coagul Fibrinolysis 12 (2001), 25–31.
167. Ranucci, M., Baryshnikova, E., Crapelli, G.B., Woodward, M.K., Paez, A., Pelissero, G., Preoperative antithrombin supplementation in cardiac surgery: a randomized controlled trial. J Thorac Cardiovasc Surg 145 (2013), 1393–1399.
168. Linkins, L.A., Dans, A.L., Moores, L.K., Bona, R., Davidson, B.L., Schulman, S., et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), e495S–e4530.
169. Warkentin, T.E., Sheppard, J.A., Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. Blood 123 (2014), 2485–2493.
170. Lo, G.K., Sigouin, C.S., Warkentin, T.E., What is the potential for overdiagnosis of heparin-induced thrombocytopenia?. Am J Hematol 82 (2007), 1037–1043.
171. Smedira, N.G., Dyke, C.M., Koster, A., Jurmann, M., Bhatia, D.S., Hu, T., et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 131 (2006), 686–692.
172. Dyke, C.M., Aldea, G., Koster, A., Smedira, N., Avery, E., Aronson, S., et al. Off-pump coronary artery bypass with bivalirudin for patients with heparininduced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg 84 (2007), 836–839.
173. Dyke, C.M., Smedira, N.G., Koster, A., Aronson, S., McCarthy, H.L. 2nd, Kirshner, R., et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 131 (2006), 533–539.
174. Koster, A., Dyke, C.M., Aldea, G., Smedira, N.G., McCarthy, H.L. 2nd, Aronson, S., et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 83 (2007), 572–577.
175. Warkentin, T.E., Greinacher, A., Koster, A., Bivalirudin. Thromb Haemost 99 (2008), 830–839.
176. Palatianos, G., Michalis, A., Alivizatos, P., Lacoumenda, S., Geroulanos, S., Karabinis, A., et al. Perioperative use of iloprost in cardiac surgery patients diagnosed with heparin-induced thrombocytopenia-reactive antibodies or with true HIT (HIT-reactive antibodies plus thrombocytopenia): an 11-year experience. Am J Hematol 90 (2015), 608–617.
177. Koster, A., Meyer, O., Fischer, T., Kukucka, M., Krabatsch, T., Bauer, M., et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. J Thorac Cardiovasc Surg 122 (2001), 1254–1255.
178. Welsby, I.J., Um, J., Milano, C.A., Ortel, T.L., Arepally, G., Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg 110 (2010), 30–35.
179. Warkentin, T.E., Sheppard, J.A., Chu, F.V., Kapoor, A., Crowther, M.A., Gangji, A., Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. Blood 125 (2015), 195–198.
180. Tran, M.H., Lin, D.M., Wilcox, T., Schiro, D., Cannesson, M., Milliken, J., Effects of a multimodality blood conservation schema toward improvement of intraoperative hemoglobin levels and off-pump transfusions in coronary artery bypass graft surgery. Transfusion 54 (2014), 2769–2774.
181. Vretzakis, G., Kleitsaki, A., Stamoulis, K., Bareka, M., Georgopoulou, S., Karanikolas, M., et al. Intra-operative intravenous fluid restriction reduces perioperative red blood cell transfusion in elective cardiac surgery, especially in transfusion-prone patients: a prospective, randomized controlled trial. J Cardiothorac Surg, 5, 2010, 7.
182. Ranucci, M., Conti, D., Castelvecchio, S., Menicanti, L., Frigiola, A., Ballotta, A., et al. Hematocrit on cardiopulmonary bypass and outcome after coronary surgery in nontransfused patients. Ann Thorac Surg 89 (2010), 11–17.
183. Martin, K., Keller, E., Gertler, R., Tassani, P., Wiesner, G., Efficiency and safety of preoperative autologous blood donation in cardiac surgery: a matched-pair analysis in 432 patients. Eur J Cardiothorac Surg 37 (2010), 1396–1401.
184. Dietrich, W., Thuermel, K., Heyde, S., Busley, R., Berger, K., Autologous blood donation in cardiac surgery: reduction of allogeneic blood transfusion and cost-effectiveness. J Cardiothorac Vasc Anesth 19 (2005), 589–596.
185. Carless, P., Moxey, A., O'Connell, D., Henry, D., Autologous transfusion techniques: a systematic review of their efficacy. Transfus Med 14 (2004), 123–144.
186. Barile, L., Fominskiy, E., Di Tomasso, N., Alpizar Castro, L.E., Landoni, G., De Luca, M., et al. Acute normovolemic hemodilution reduces allogeneic red blood cell transfusion in cardiac surgery: a systematic review and metaanalysis of randomized trials. Anesth Analg 124 (2017), 743–752.
187. Osawa, E.A., Rhodes, A., Landoni, G., Galas, F.R., Fukushima, J.T., Park, C.H., et al. Effect of perioperative goal-directed hemodynamic resuscitation therapy on outcomes following cardiac surgery: a randomized clinical trial and systematic review. Crit Care Med 44 (2016), 724–733.
188. Damen, T., Reinsfelt, B., Redfors, B., Nygren, A., Pressure-dependent changes in haematocrit and plasma volume during anaesthesia, a randomised clinical trial. Acta Anaesthesiol Scand 60 (2016), 560–568.
189. Goepfert, M.S., Richter, H.P., Zu Eulenburg, C., Gruetzmacher, J., Rafflenbeul, E., Roeher, K., et al. Individually optimized hemodynamic therapy reduces complications and length of stay in the intensive care unit: a prospective, randomized controlled trial. Anesthesiology 119 (2013), 824–836.
190. Bethlehem, I., Wierda, K., Visser, C., Jekel, L., Koopmans, M., Kuiper, M.A., Influence of two colloidal extracorporeal primes on coagulation of cardiac surgical patients: a prospectively randomized open-label pilot trial. J Extra Corpor Technol 46 (2014), 293–299.
191. Cho, J.-E., Shim, J.-K., Song, J.-W., Song, J.-W., Lee, H.-W., Kim, D.-H., et al. Effect of 6% hydroxyethyl starch 130/0.4 as a priming solution on coagulation and inflammation following complex heart surgery. Yonsei Med J 55 (2014), 625–634.
192. Kuitunen, A.H., Hynynen, M.J., Vahtera, E., Salmenpera, M.T., Hydroxyethyl starch as a priming solution for cardiopulmonary bypass impairs hemostasis after cardiac surgery. Anesth Analg 98 (2004), 291–297.
193. Schramko, A., Suojaranta-Ylinen, R., Niemi, T., Pesonen, E., Kuitunen, A., Raivio, P., et al. The use of balanced HES 130/0.42 during complex cardiac surgery; effect on blood coagulation and fluid balance: a randomized controlled trial. Perfusion 30 (2015), 224–232.
194. Kamra, C., Beney, A., Human albumin in extracorporeal prime: effect on platelet function and bleeding. Perfusion 28 (2013), 536–540.
195. Van der Linden, P.J., De Hert, S.G., Daper, A., Trenchant, A., Schmartz, D., Defrance, P., et al. 3.5% urea-linked gelatin is as effective as 6% HES 200/0.5 for volume management in cardiac surgery patients. Can J Anesth 51 (2004), 236–241.
196. Kasper, S.M., Meinert, P., Kampe, S., Gorg, C., Geisen, C., Mehlhorn, U., et al. Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses. Anesthesiology 99 (2003), 42–47.
197. Gurbuz, H.A., Durukan, A.B., Salman, N., Tavlasoglu, M., Durukan, E., Ucar, H.I., et al. Hydroxyethyl starch 6%, 130/0.4 vs. a balanced crystalloid solution in cardiopulmonary bypass priming: a randomized, prospective study. J Cardiothorac Surg, 8, 2013, 71.
198. Min, J.O.S., Ramzisham, A.R.M., Zamrin, M.D., Is 6% hydroxyethyl starch 130/0.4 safe in coronary artery bypass graft surgery?. Asian Cardiovasc Thorac Ann 17 (2009), 368–372.
199. Vanhoonacker, J., Ongenae, M., Vanoverschelde, H., Donadoni, R., Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for cardiopulmonary bypass priming: the effects on postoperative bleeding and volume expansion needs after elective CABG. Acta Anaesthesiol Belg 60 (2009), 91–97.
200. Hecht-Dolnik, M., Barkan, H., Taharka, A., Loftus, J., Hetastarch increases the risk of bleeding complications in patients after off-pump coronary bypass surgery: a randomized clinical trial. J Thorac Cardiovasc Surg 138 (2009), 703–711.
201. Van der Linden, P.J., De Hert, S.G., Deraedt, D., Cromheecke, S., De Decker, K., De Paep, R., et al. Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on perioperative bleeding and transfusion needs. Anesth Analg 101 (2005), 629–634.
202. Skhirtladze, K., Base, E.M., Lassnigg, A., Kaider, A., Linke, S., Dworschak, M., et al. Comparison of the effects of albumin 5%, hydroxyethyl starch 130/0.4 6%, and Ringer's lactate on blood loss and coagulation after cardiac surgery. Br J Anaesth 112 (2014), 255–264.
203. DeFoe, G.R., Ross, C.S., Olmstead, E.M., Surgenor, S.D., Fillinger, M.P., Groom, R.C., et al. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg 71 (2001), 769–776.
204. Lewis, C.E., Hiratzka, L.F., Woods, S.E., Hendy, M.P., Engel, A.M., Autologous blood transfusion in elective cardiac valve operations. J Card Surg 20 (2005), 513–518.
205. Myles, P.S., Smith, J.A., Forbes, A., Silbert, B., Jayarajah, M., Painter, T., et al. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med 376 (2017), 136–148.
206. Henry, D.A., Carless, P.A., Moxey, A.J., O'Connell, D., Stokes, B.J., Fergusson, D.A., et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev, 3, 2011 CD001886.
207. Sedrakyan, A., Treasure, T., Elefteriades, J.A., Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 128 (2004), 442–448.
208. Desborough, M., Sandu, R., Brunskill, S.J., Doree, C., Trivella, M., Montedori, A., et al. Fresh frozen plasma for cardiovascular surgery. Cochrane Database Syst Rev, 7, 2015 CD007614.
209. Stanworth, S.J., Brunskill, S.J., Hyde, C.J., McClelland, D.B., Murphy, M.F., Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 126 (2004), 139–152.
210. Casbard, A.C., Williamson, L.M., Murphy, M.F., Rege, K., Johnson, T., The role of prophylactic fresh frozen plasma in decreasing blood loss and correcting coagulopathy in cardiac surgery. A systematic review. Anaesthesia 59 (2004), 550–558.
211. Demeyere, R., Gillardin, S., Arnout, J., Strengers, P.F., Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 99 (2010), 251–260.
212. Johansen, M., Wikkelso, A., Lunde, J., Wetterslev, J., Afshari, A., Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients. Cochrane Database Syst Rev, 7, 2015 CD010555.
213. Godje, O., Gallmeier, U., Schelian, M., Grunewald, M., Mair, H., Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg 54 (2006), 26–33.
214. Karkouti, K., von Heymann, C., Jespersen, C.M., Korte, W., Levy, J.H., Ranucci, M., et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. J Thorac Cardiovasc Surg 146 (2013), 927–939.
215. Bilecen, S., de Groot, J.A., Kalkman, C.J., Spanjersberg, A.J., Brandon Bravo Bruinsma, G.J., Moons, K.G., et al. Effect of fibrinogen concentrate on intraoperative blood loss among patients with intraoperative bleeding during high-risk cardiac surgery: a randomized clinical trial. JAMA 317 (2017), 738–747.
216. Wikkelso, A., Lunde, J., Johansen, M., Stensballe, J., Wetterslev, J., Moller, A.M., et al. Fibrinogen concentrate in bleeding patients. Cochrane Database Syst Rev, 8, 2013 CD008864.
217. Fassl, J., Matt, P., Eckstein, F., Filipovic, M., Gregor, M., Zenklusen, U., et al. Transfusion of allogeneic blood products in proximal aortic surgery with hypothermic circulatory arrest: effect of thromboelastometry-guided transfusion management. J Cardiothorac Vasc Anesth 27 (2013), 1181–1188.
218. Bilecen, S., Peelen, L.M., Kalkman, C.J., Spanjersberg, A.J., Moons, K.G., Nierich, A.P., Fibrinogen concentrate therapy in complex cardiac surgery. J Cardiothorac Vasc Anesth 27 (2013), 12–17.
219. Ortmann, E., Besser, M.W., Sharples, L.D., Gerrard, C., Berman, M., Jenkins, D.P., et al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesth Analg 121 (2015), 26–33.
220. Bolliger, D., Gorlinger, K., Tanaka, K.A., Pathophysiology and treatment of coagulopathyin massive hemorrhage and hemodilution. Anesthesiology 113 (2010), 1205–1219.
221. Bignami, E., Cattaneo, M., Crescenzi, G., Ranucci, M., Guarracino, F., Cariello, C., et al. Desmopressin after cardiac surgery in bleeding patients. A multicenter randomized trial. Acta Anaesthesiol Scand 60 (2016), 892–900.
222. Wademan, B.H., Galvin, S.D., Desmopressin for reducing postoperative blood loss and transfusion requirements following cardiac surgery in adults. Interact CardioVasc Thorac Surg 18 (2014), 360–370.
223. Gill, R., Herbertson, M., Vuylsteke, A., Olsen, P.S., von Heymann, C., Mythen, M., et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 120 (2009), 21–27.
224. Simpson, E., Lin, Y., Stanworth, S., Birchall, J., Doree, C., Hyde, C., Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev, 3, 2012 CD005011.
225. Adler Ma, S.C., Brindle, W., Burton, G., Gallacher, S., Hong, F.C., Manelius, I., et al. Tranexamic acid is associated with less blood transfusion in offpump coronary artery bypass graft surgery: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 25 (2011), 26–35.
226. Ker, K., Edwards, P., Perel, P., Shakur, H., Roberts, I., Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. Br Med J, 344, 2012, e3054.
227. Sharma, V., Katznelson, R., Jerath, A., Garrido-Olivares, L., Carroll, J., Rao, V., et al. The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients. Anaesthesia 69 (2014), 124–130.
228. Koster, A., Borgermann, J., Zittermann, A., Lueth, J.U., Gillis-Januszewski, T., Schirmer, U., Moderate dosage of tranexamic acid during cardiac surgery with cardiopulmonary bypass and convulsive seizures: incidence and clinical outcome. Br J Anaesth 110 (2013), 34–40.
229. Karkouti, K., Beattie, W.S., Dattilo, K.M., McCluskey, S.A., Ghannam, M., Hamdy, A., et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 46 (2006), 327–338.
230. Mangano, D.T., Tudor, I.C., Dietzel, C. Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006), 353–365.
231. Walkden, G.J., Verheyden, V., Goudie, R., Murphy, G.J., Increased periopera-tive mortality following aprotinin withdrawal: a real-world analysis of blood management strategies in adult cardiac surgery. Intensive Care Med 39 (2013), 1808–1817.
232. Howell, N., Senanayake, E., Freemantle, N., Pagano, D., Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin. J Thorac Cardiovasc Surg 145 (2013), 234–240.
233. Pagano, D., Howell, N.J., Freemantle, N., Cunningham, D., Bonser, R.S., Graham, T.R., et al. Bleeding in cardiac surgery: the use of aprotinin does not affect survival. J Thorac Cardiovasc Surg 135 (2008), 495–502.
234. Fergusson, D.A., Hebert, P.C., Mazer, C.D., Fremes, S., MacAdams, C., Murkin, J.M., et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358 (2008), 2319–2331.
235. McMullan, V., Alston, R.P., III. Aprotinin and cardiac surgery: a sorry tale of evidence misused. Br J Anaesth 110 (2013), 675–678.
236. Canada H. Health Canada Decision on Trasylol (Aprotinin) (21 September 2011, date last accessed).
237. Agency E. European Medicines Agency Recommends Lifting Suspension of Aprotinin; Review Finds That Benefits of All Antifibrinolytic Medicines Outweigh Risks in Restricted Range of Indications (17 February 2012, date last accessed).
238. Yang, L., Stanworth, S., Hopewell, S., Doree, C., Murphy, M., Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion 52 (2012), 1673–1686 quiz.
239. Karkouti, K., McCluskey, S.A., Syed, S., Pazaratz, C., Poonawala, H., Crowther, M.A., The influence of perioperative coagulation status on postoperative blood loss in complex cardiac surgery: a prospective observational study. Anesth Analg 110 (2010), 1533–1540.
240. Ternstrom, L., Radulovic, V., Karlsson, M., Baghaei, F., Hyllner, M., Bylock, A., et al. Plasma activity of individual coagulation factors, hemodilution and blood loss after cardiac surgery: a prospective observational study. Thromb Res 126 (2010), e128–e133.
241. Theusinger, O.M., Baulig, W., Asmis, L.M., Seifert, B., Spahn, D.R., In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM). Thromb Haemost 104 (2010), 385–391.
242. Karkouti, K., Callum, J., Crowther, M.A., McCluskey, S.A., Pendergrast, J., Tait, G., et al. The relationship between fibrinogen levels after cardiopulmonary bypass and large volume red cell transfusion in cardiac surgery: an observational study. Anesth Analg 117 (2013), 14–22.
243. Levy, J.H., Gill, R., Nussmeier, N.A., Olsen, P.S., Andersen, H.F., Booth, F.V., et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary report. Thromb Haemost 102 (2009), 765–771.
244. Hiippala, S.T., Myllyla, G.J., Vahtera, E.M., Hemostatic factors and replace-ment of major blood loss with plasma-poor red cell concentrates. Anesth Analg 81 (1995), 360–365.
245. Bolliger, D., Gonsahn, M., Levy, J.H., Williams, W.H., Tanaka, K.A., Is preoperative fibrinogen predictive for postoperative bleeding after coronary artery bypass grafting surgery?. Transfusion 49 (2009), 2006–2007 author reply 7–8.
246. Tanaka, K.A., Esper, S., Bolliger, D., Perioperative factor concentrate therapy. Br J Anaesth 111:Suppl 1 (2013), i35–i49.
247. Jeppsson, A., Walden, K., Roman-Emanuel, C., Thimour-Bergstrom, L., Karlsson, M., Preoperative supplementation with fibrinogen concentrate in cardiac surgery: a randomized controlled study. Br J Anaesth 116 (2016), 208–214.
248. Rahe-Meyer, N., Solomon, C., Hanke, A., Schmidt, D.S., Knoerzer, D., Hochleitner, G., et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebocontrolled trial. Anesthesiology 118 (2013), 40–50.
249. Ranucci, M., Baryshnikova, E., Crapelli, G.B., Rahe-Meyer, N., Menicanti, L., Frigiola, A., Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J Am Heart Assoc, 4, 2015 e002066.
250. Rahe-Meyer, N., Levy, J.H., Mazer, C.D., Schramko, A., Klein, A.A., Brat, R., et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. Br J Anaesth 117 (2016), 41–51.
251. Ranucci, M., Baryshnikova, E., Fibrinogen supplementation after cardiac surgery: insights from the Zero-Plasma trial (ZEPLAST). Br J Anaesth 116 (2016), 618–623.
252. Fassl, J., Lurati Buse, G., Filipovic, M., Reuthebuch, O., Hampl, K., Seeberger, M.D., et al. Perioperative administration of fibrinogen does not increase adverse cardiac and thromboembolic events after cardiac surgery. Br J Anaesth 114 (2015), 225–234.
253. Ghadimi, K., Levy, J.H., Welsby, I.J., Prothrombin complex concentrates for bleeding in the perioperative setting. Anesth Analg 122 (2016), 1287–1300.
254. Arnekian, V., Camous, J., Fattal, S., Rezaiguia-Delclaux, S., Nottin, R., Stephan, F., Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interact CardioVasc Thorac Surg 15 (2012), 382–389.
255. Cappabianca, G., Mariscalco, G., Biancari, F., Maselli, D., Papesso, F., Cottini, M., et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Crit Care, 20, 2016, 5.
256. Carless, P.A., Henry, D.A., Moxey, A.J., O'Connell, D., McClelland, B., Henderson, K.M., et al. Desmopressin for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev, 1, 2004 CD001884.
257. Crescenzi, G., Landoni, G., Biondi-Zoccai, G., Pappalardo, F., Nuzzi, M., Bignami, E., et al. Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. Anesthesiology 109 (2008), 1063–1076.
258. Desborough, M.J., Oakland, K.A., Landoni, G., Crivellari, M., Doree, C., Estcourt, L.J., et al. Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 15 (2017), 263–272.
259. Steiner, M.E., Ness, P.M., Assmann, S.F., Triulzi, D.J., Sloan, S.R., Delaney, M., et al. Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med 372 (2015), 1419–1429.
260. Lacroix, J., Hebert, P.C., Fergusson, D.A., Tinmouth, A., Cook, D.J., Marshall, J.C., et al. Age of transfused blood in critically ill adults. N Engl J Med 372 (2015), 1410–1418.
261. Dzieciatkowska, M., Silliman, C.C., Moore, E.E., Kelher, M.R., Banerjee, A., Land, K.J., et al. Proteomic analysis of the supernatant of red blood cell units: the effects of storage and leucoreduction. Vox Sang 105 (2013), 210–218.
262. Membe, S.K., Coyle, D., Husereau, D., Cimon, K., Tinmouth, A., Normandin, S., Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis [Internet]., 2011.
263. Deppe, A.C., Weber, C., Zimmermann, J., Kuhn, E.W., Slottosch, I., Liakopoulos, O.J., et al. Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. J Surg Res 203 (2016), 424–433.
264. Serraino, G.F., Murphy, G.J., Routine use of viscoelastic blood tests for diag-nosis and treatment of coagulopathic bleeding in cardiac surgery: updated systematic review and meta-analysis. Br J Anaesth 118 (2017), 823–833.
265. Karkouti, K., Callum, J., Wijeysundera, D.N., Rao, V., Crowther, M., Grocott, H.P., et al. Point-of-care hemostatic testing in cardiac surgery: a stepped-wedge clustered randomized controlled trial. Circulation 134 (2016), 1152–1162.
266. Murphy, G.J., Pike, K., Rogers, C.A., Wordsworth, S., Stokes, E.A., Angelini, G.D., et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med 372 (2015), 997–1008.
267. Hajjar, L.A., Vincent, J.L., Galas, F.R., Nakamura, R.E., Silva, C.M., Santos, M.H., et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA 304 (2010), 1559–1567.
268. von Heymann, C., Sander, M., Foer, A., Heinemann, A., Spiess, B., Braun, J., et al. The impact of an hematocrit of 20% during normothermic cardiopulmonary bypass for elective low risk coronary artery bypass graft surgery on oxygen delivery and clinical outcome–a randomized controlled study [ISRCTN35655335]. Crit Care, 10, 2006, R58.
269. Klausen, S.S., Hervig, T., Seghatchian, J., Reikvam, H., Bacterial contamination of blood components: Norwegian strategies in identifying donors with higher risk of inducing septic transfusion reactions in recipients. Transfus Apher Sci 51 (2014), 97–102.
270. Dwyre, D.M., Fernando, L.P., Holland, P.V., Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang 100 (2011), 92–98.
271. Shaz, B.H., Stowell, S.R., Hillyer, C.D., Transfusion-related acute lung injury: from bedside to bench and back. Blood 117 (2011), 1463–1471.
272. Dunbar, N.M., Current options for transfusion-related acute lung injury risk mitigation in platelet transfusions. Curr Opin Hematol 22 (2015), 554–558.
273. Vamvakas, E.C., Blajchman, M.A., Transfusion-related immunomodulation (TRIM): an update. Blood Rev 21 (2007), 327–348.
274. Blumberg, N., Zhao, H., Wang, H., Messing, S., Heal, J.M., Lyman, G.H., The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion 47 (2007), 573–581.
275. Rohde, J.M., Dimcheff, D.E., Blumberg, N., Saint, S., Langa, K.M., Kuhn, L., et al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA 311 (2014), 1317–1326.
276. Bilgin, Y.M., van de Watering, L.M., Eijsman, L., Versteegh, M.I., Brand, R., van Oers, M.H., et al. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation 109 (2004), 2755–2760.
277. Sartipy, U., Holzmann, M.J., Hjalgrim, H., Edgren, G., Red blood cell concentrate storage and survival after cardiac surgery. JAMA 314 (2015), 1641–1643.
278. Alexander, P.E., Barty, R., Fei, Y., Vandvik, P.O., Pai, M., Siemieniuk, R.A., et al. Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis. Blood 127 (2016), 400–410.
279. Vamvakas, E.C., Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion 49 (2009), 2743–2758.
280. Welsby, I.J., Lockhart, E., Phillips-Bute, B., Campbell, M.L., Mathew, J.P., Newman, M.F., et al. Storage age of transfused platelets and outcomes after cardiac surgery. Transfusion 50 (2010), 2311–2317.
281. Ogawa, S., Szlam, F., Bolliger, D., Nishimura, T., Chen, E.P., Tanaka, K.A., The impact of hematocrit on fibrin clot formation assessed by rotational thromboelastometry. Anesth Analg 115 (2012), 16–21.
282. Wikkelso, A., Wetterslev, J., Moller, A.M., Afshari, A., Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev, 8, 2016 CD007871.
283. Whiting, P., Al, M., Westwood, M., Ramos, I.C., Ryder, S., Armstrong, N., et al. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and costeffectiveness analysis. Health Technol Assess 19 (2015), 1–228 v–vi.
284. Weber, C.F., Gorlinger, K., Meininger, D., Herrmann, E., Bingold, T., Moritz, A., et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 117 (2012), 531–547.
285. Song, H.K., von Heymann, C., Jespersen, C.M., Karkouti, K., Korte, W., Levy, J.H., et al. Safe application of a restrictive transfusion protocol in moderate-risk patients undergoing cardiac operations. Ann Thorac Surg 97 (2014), 1630–1635.
286. Ranucci, M., Aloisio, T., Carboni, G., Ballotta, A., Pistuddi, V., Menicanti, L., et al. Acute kidney injury and hemodilution during cardiopulmonary bypass: a changing scenario. Ann Thorac Surg 100 (2015), 95–100.
287. Patel, N.N., Avlonitis, V.S., Jones, H.E., Reeves, B.C., Sterne, J.A., Murphy, G.J., Indications for red blood cell transfusion in cardiac surgery: a systematic review and meta-analysis. Lancet Haematol 2 (2015), e543–e553.
288. Nakamura, R.E., Vincent, J.L., Fukushima, J.T., de Almeida, J.P., Franco, R.A., Lee Park, C., et al. A liberal strategy of red blood cell transfusion reduces cardiogenic shock in elderly patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 150 (2015), 1314–1320.
289. Kumar, A., Mhaskar, R., Grossman, B.J., Kaufman, R.M., Tobian, A.A., Kleinman, S., et al. Platelet transfusion: a systematic review of the clinical evidence. Transfusion 55 (2015), 1116–1127 quiz 5.
290. Kaufman, R.M., Djulbegovic, B., Gernsheimer, T., Kleinman, S., Tinmouth, A.T., Capocelli, K.E., et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 162 (2015), 205–213.
291. Annich, G.M., Extracorporeal life support: the precarious balance of hemostasis. J Thromb Haemost 13:Suppl 1 (2015), S336–S342.
292. Bates, S.M., Weitz, J.I., Coagulation assays. Circulation 112 (2005), e53–e60.
293. Wool, G.D., Lu, C.M., Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Pathology consultation on anticoagulation monitoring: factor X-related assays. Am J Clin Pathol 140 (2013), 623–634.
294. Price, E.A., Jin, J., Nguyen, H.M., Krishnan, G., Bowen, R., Zehnder, J.L., Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Ann Pharmacother 47 (2013), 151–158.
295. Adatya, S., Uriel, N., Yarmohammadi, H., Holley, C.T., Feng, A., Roy, S.S., et al. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support. JACC Heart Fail 3 (2015), 314–322.
296. Koster, A., Chew, D., Grundel, M., Hausmann, H., Grauhan, O., Kuppe, H., et al. An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study. Anesth Analg 96 (2003), 1316–1319.
297. Hoechter, D.J., von Dossow, V., Winter, H., Muller, H.H., Meiser, B., Neurohr, C., et al. The munich lung transplant group: intraoperative extracorporeal circulation in lung transplantation. Thorac Cardiovasc Surg 63 (2015), 706–714.
298. Bembea, M.M., Annich, G., Rycus, P., Oldenburg, G., Berkowitz, I., Pronovost, P., Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med 14 (2013), e77–e84.
299. Chu, D.C., Abu-Samra, A.G., Baird, G.L., Devers, C., Sweeney, J., Levy, M.M., et al. Quantitative measurement of heparin in comparison with conventional anticoagulation monitoring and the risk of thrombotic events in adults on extracorporeal membrane oxygenation. Intensive Care Med 41 (2015), 369–370.
300. Yeo, H.J., Kim do, H., Jeon, D., Kim, Y.S., Cho, W.H., Low-dose heparin during extracorporeal membrane oxygenation treatment in adults. Intensive Care Med 41 (2015), 2020–2021.
301. Byrnes, J.W., Swearingen, C.J., Prodhan, P., Fiser, R., Dyamenahalli, U., Antithrombin III supplementation on extracorporeal membrane oxygenation: impact on heparin dose and circuit life. ASAIO J 60 (2014), 57–62.
302. Ranucci, M., Baryshnikova, E., Cotza, M., Carboni, G., Isgro, G., Carlucci, C., et al. Coagulation monitoring in postcardiotomy ECMO: conventional tests, point-of-care, or both?. Minerva Anestesiol 82 (2016), 858–866.
303. Ranucci, M., Ballotta, A., Kandil, H., Isgro, G., Carlucci, C., Baryshnikova, E., et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care, 15, 2011, R275.
304. Pieri, M., Agracheva, N., Bonaveglio, E., Greco, T., De Bonis, M., Covello, R.D., et al. Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study. J Cardiothorac Vasc Anesth 27 (2013), 30–34.
305. Beiderlinden, M., Treschan, T., Gorlinger, K., Peters, J., Argatroban in extra-corporeal membrane oxygenation. Artif Organs 31 (2007), 461–465.